Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:RMBS News 3 January 2026 - 3 February 2026

Rambus stock dives 14% premarket after earnings as supply snag dents near-term outlook

Rambus stock dives 14% premarket after earnings as supply snag dents near-term outlook

Rambus shares fell 14.4% to $97.37 in premarket trading Tuesday after the company reported a one-time supply chain disruption that will hit near-term shipments. Fourth-quarter GAAP revenue reached $190.2 million, with record product sales of $96.8 million. The company projected lower product revenue for Q1 and warned that meeting targets depends on new contracts.
3 February 2026
··
Rambus stock sinks into earnings week after sharp Friday reversal in RMBS

Rambus stock sinks into earnings week after sharp Friday reversal in RMBS

Rambus shares fell 6.39% to $113.83 at Friday’s close, reversing early gains ahead of its earnings report due after the bell Monday. The stock swung between $112.84 and $127.03 during the session. Chip stocks and major indexes dropped as investors reacted to higher-than-expected producer prices and uncertainty over the next Federal Reserve chair. U.S. markets are closed for the weekend.
1 February 2026
··
Rambus (RMBS) stock spikes 18% to a fresh high as chip rally builds ahead of Feb. 2 results

Rambus (RMBS) stock spikes 18% to a fresh high as chip rally builds ahead of Feb. 2 results

Rambus shares jumped 18% to $130.26 by late morning Wednesday, hitting a 52-week high amid a broad chip sector rally. Intel rose 11%, AMD and Micron gained about 8%, and the iShares Semiconductor ETF climbed 3%. Investors are focused on Rambus’ Feb. 2 earnings call for updates on data-center memory demand. Trading volume in Rambus topped 2.8 million shares by midday.
21 January 2026
··
Rambus stock (RMBS) jumps 8% to near $100 as chip rally kicks off 2026 — what investors watch next

Rambus stock (RMBS) jumps 8% to near $100 as chip rally kicks off 2026 — what investors watch next

NEW YORK, January 3, 2026, 04:59 ET — Market closed Rambus Inc (RMBS) jumped 8.0% on Friday to close at $99.28. The Nasdaq-listed stock traded between $95.21 and $100.68 and finished up from a prior close of $91.89, while still below its 52-week high of $114.55, the company’s investor relations site showed. The move came as semiconductor shares led a broader Wall Street rebound on the first trading day of 2026, with the Philadelphia SE Semiconductor index (.SOX) — a gauge of major U.S. chip stocks — up 4%. “The market is seeing a ‘buy the dip, sell the rip’
3 January 2026
··

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop